KRAS and lung adenocarcinoma: This contrasts with human lung adenocarcinomas, in which mutant K-ras is thought of as oncogenic driver and of which between 19 and 33% were shown to harbor oncogenic KRAS mutations (Cancer Genome Atlas Research Network, 2014; Wu et al., 2015).